Cingulate (NASDAQ:CING) Coverage Initiated at Roth Mkm

Stock analysts at Roth Mkm began coverage on shares of Cingulate (NASDAQ:CING) in a research note issued on Friday, Marketbeat reports. The firm set a “buy” rating and a $12.00 price target on the stock. Roth Mkm’s price objective indicates a potential upside of 149.48% from the company’s current price.

Separately, Maxim Group raised shares of Cingulate from a “hold” rating to a “buy” rating in a research note on Wednesday, November 20th.

Cingulate Stock Up 11.6 %

Shares of NASDAQ:CING opened at $4.81 on Friday. The business has a fifty day simple moving average of $4.36 and a 200-day simple moving average of $4.13. Cingulate has a 52 week low of $1.80 and a 52 week high of $88.44.

Cingulate (NASDAQ:CING) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($1.83) earnings per share for the quarter, topping the consensus estimate of ($2.22) by $0.39. On average, equities analysts forecast that Cingulate will post -9.26 EPS for the current fiscal year.

Institutional Trading of Cingulate

An institutional investor recently bought a new position in Cingulate stock. Jane Street Group LLC bought a new stake in Cingulate Inc. (NASDAQ:CING) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 21,031 shares of the company’s stock, valued at approximately $106,000. Jane Street Group LLC owned 0.66% of Cingulate at the end of the most recent quarter. 41.31% of the stock is owned by hedge funds and other institutional investors.

Cingulate Company Profile

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.